ACADIA Pharmaceuticals Inc.NASDAQ: ACAD

Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference

· Issued by ACADIA Pharmaceuticals Inc. via Business Wire

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the Guggenheim Securities 5th Annual Inflammation & Immunology (I&I) Conference on Tuesday, November 7, 2023 at 4:30 p.m. Eastern Time.

A live webcast of the presentation will be accessible on the company’s website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.

Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818) 395-3043 [email protected]

Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858) 261-2872 [email protected]

Acadia Pharmaceuticals Inc. Jessica Tieszen (858) 261-2950 [email protected]

Source: Acadia Pharmaceuticals Inc.

View original source (Business Wire)ACADIA Pharmaceuticals Inc. on 6ix

In the deck

Earlier from ACADIA Pharmaceuticals

Later from ACADIA Pharmaceuticals

All ACADIA Pharmaceuticals news releases